Brief: Spruce Biosciences Announces New Corporate Strategy And Acquisition Of Tralesinidase Alfa
15/04/2025 12:09
April 15 (Reuters) - Spruce Biosciences Inc SPRB.O: SPRUCE BIOSCIENCES ANNOUNCES NEW CORPORATE STRATEGY AND ACQUISITION OF TRALESINIDASE ALFA FOR THE TREATMENT OF SANFILIPPO SYNDROME TYPE B (MPS IIIB) SPRUCE BIOSCIENCES INC - BLA SUBMISSION TO FDA FOR TA-ERT ANTICIPATED IN 1H 2026 SPRUCE BIOSCIENCES INC: EXPECTS ITS CASH RUNWAY TO FUND ITS CURRENT OPERATING PLAN THROUGH END OF 2025 Source text: ID:nBw1JyyWJa Further company coverage: SPRB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spruce Biosciences
See all newsSpruce Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Spruce Biosciences Q2 net loss widens on higher expenses
Spruce Biosciences, Inc. expected to post a loss of $5.80 a share - Earnings Preview
Brief: Spruce Biosciences Appoints Adrian Quartel, M.D., Ffpm, As Chief Medical Officer
Brief: Spruce Biosciences Announces Data Presentation At The 18Th International MPS Symposium